The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances. LumiraDx’s transformative Point of Care solution will complement Roche’s diagnostics portfolio across Clinical...

The World Health Organization (WHO) has awarded the Roche human papillomavirus (HPV) test prequalification designations for use on the cobas 5800 System and for self-collected samples on the cobas 5800, 6800 and 8800 Systems. These...

The solution, which includes the VENTANA DP 200 slide scanner, Roche’s digital pathology workflow software and a display, is now cleared to aid in clinical diagnosis, enabling pathologists to diagnose patients using digital...

Roche (RHHBY) said that it has received CE Mark approval for the VENTANA HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx, enabling the identification of metastatic breast cancer patients with low HER2 expression who may benefit from ENHERTU...

PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business. The image analysis algorithms will be deployed on Roche's...

Roche’s navify Digital Pathology software platform now offers Ibex’s Artificial Intelligence (AI) algorithms to support clinicians in the diagnosis of breast and prostate cancer. Roche and Ibex cloud-based digital...